1 / 13

Influenza Virus Vaccine 2009-2010 Strain Selection

Influenza Virus Vaccine 2009-2010 Strain Selection. Jerry P. Weir, Ph.D. Director, Division of Viral Products CBER/FDA Prepared for Vaccines and Related Biological Products Advisory Committee 18 February 2009. Purpose of Today’s VRBPAC Committee Discussion.

kapila
Download Presentation

Influenza Virus Vaccine 2009-2010 Strain Selection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Influenza Virus Vaccine2009-2010 Strain Selection Jerry P. Weir, Ph.D. Director, Division of Viral Products CBER/FDA Prepared for Vaccines and Related Biological Products Advisory Committee 18 February 2009

  2. Purpose of Today’s VRBPAC Committee Discussion • Make recommendations for the strains of influenza A (H1N1 and H3N2) and B viruses to be included in 2009-2010 influenza vaccines for use in the United States

  3. Why Consider Strain Changes in Influenza Vaccines? Vaccine efficacy relates to: • Vaccine potency (immunogenicity) • Match of vaccine HA/NA with wild-type viruses • Antigenic drift of HA/NA continuous in influenza A and B viruses • Evidence of reduced vaccine effectiveness resulting from antigenic drift observed within 2 years after influenza vaccines first licensed for use in United States

  4. Questions to Be Answered forStrain Changes Every Year • Are new (drifted or shifted) influenza viruses present? • Are these new viruses spreading in people? • Do current vaccines induce antibodies against the new viruses (HA)? • Are strains suitable for vaccines available?

  5. Types of Analyses Used forVaccine Strain Selection • Antigenic relationships among contemporary viruses and candidate vaccine strains • Hemagglutination inhibition (HI) tests using post-infection ferret sera • Virus neutralization tests • HI tests using panels of sera from humans receiving TIV • Antigenic cartography • Phylogenetic analyses of HA and NA genes • Epidemiology of circulating strains • Availability and characteristics of egg-derived vaccine strains and high-growth reassortants

  6. Review of Influenza Strain Selectionfor 2008-2009 • H1N1 • 2007-2008 vaccine contained an A/Solomon Islands/3/2006-like virus strain • By February 2008, an increasing % of H1N1 viruses were antigenically distinguishable from the vaccine strain • Recommendation was made to switch the H1N1 vaccine strain to an A/Brisbane/59/2007-like virus for 2008-2009 • H3N2 • 2007-2008 vaccine contained an A/Wisconsin/67/2005-like virus strain • By February 2008, an increasing % of H3N2 viruses were antigenically distinguishable from the vaccine strain Recommendation was made to switch the H3N2 vaccine strain to an A/Brisbane/10/2007-like virus for 2008-2009

  7. Review of Influenza Strain Selectionfor 2008-2009 (Cont.) • B • 2007-2008 vaccine contained a B/Malaysia/2506/2004-like virus strain (B/Victoria lineage – 2nd consecutive year) • In February 2008, both lineages circulating, but B/Yamagata-like viruses predominated. Of the isolated B/Victoria-like viruses, increased heterogeneity to the vaccine strain observed. • Recommendation was made to switch the B vaccine strain to a B/Florida/4/2006-like virus (B/Yamagata lineage) for 2008-2009 • Vaccine situation during 2008-2009 influenza season • All three strain components changed from previous 2007-2008 NH vaccine • Recommendations for U.S. vaccine composition same as WHO • Preparation of vaccine was on schedule and supply plentiful

  8. Current Licensed seasonal InfluenzaVaccines (U.S.) • Inactivated seasonal influenza vaccines • Fluzone (Sanofi-Pasteur) • Fluvirin (Novartis) • Fluarix (GSK) • FluLaval (ID Biomedical [GSK]) • Afluria (CSL) • Live attenuated seasonal influenza vaccine • FluMist (MedImmune)

  9. Timelines for Vaccine Production

  10. WHO Consultation on the Composition of Vaccines for the Northern Hemisphere, 2008-2009 • February 9-11, 2009 • Analyze the antigenic and genetic characteristics of seasonal influenza strains circulating globally, taking into consideration epidemiological data on influenza obtained from individual countries and regions. • Make recommendations on the composition of the influenza vaccine for the northern hemisphere 2009 - 2010. • www.who.int/csr/disease/influenza/recommendations2009_10north/en/index/html

  11. WHO Recommendations for Influenza Vaccine CompositionNorthern Hemisphere: 2009-2010 • “It is recommended that vaccines for use in the 2009-2010 influenza season (northern hemisphere winter) contain the following: • an A/Brisbane/59/2007 (H1N1)-like virus • an A/Brisbane/10/2007 (H3N2)-like virus • a B/Brisbane/60/2008-like virus” • “As in previous years, national control authorities should approve the specific vaccine viruses used in each country” – VRBPAC and CBER

  12. Committee Discussion • What strains should be recommended for the antigenic composition of the 2009-2010 influenza virus vaccine based on: • the epidemiology and antigenic characteristics of influenza virus strains circulating in human populations • the serologic responses to circulating influenza viruses of persons immunized with current influenza virus vaccines, and • the availability of suitable vaccine candidate strains

  13. Options for Strain Composition for 2009-2010 Influenza Vaccines • Influenza A (H1N1) • Retain current vaccine strain A/Brisbane/59/2007 (H1N1)-like virus • e.g., A/Brisbane/59/2007; A/South Dakota/6/2007 • Replace current vaccine strain with alternative H1N1 isolate • Other candidates? • Influenza A (H3N2) • Retain current strain A/Brisbane/10/2007 (H3N2)-like virus • e.g., A/Brisbane/10/2007; A/Uruguay/716/2007 • Replace current vaccine strain with alternative H3N2 isolate • Other candidates? • Influenza B • Retain current B/Florida/4/2006-like virus (B/Yamagata lineage) • Replace current vaccine strain with alternative • B/Brisbane/60/2008-like virus (B/Victoria lineage) • e.g., B/Brisbane/60/2008; B/Brisbane/33/2008 • Other candidates?

More Related